BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30216091)

  • 1. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
    Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H
    Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
    Pan EY; Sobieraj DM
    Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
    Patti G; Haas S
    J Cardiovasc Pharmacol; 2020 Oct; 77(1):11-21. PubMed ID: 33060545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E; Horinaka S; Ishimitsu T; Kato T
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
    Masotti L; Grifoni E; Dei A; Vannucchi V; Moroni F; Spolveri S; Panigada G; Landini G
    Thromb Res; 2018 Dec; 172():165-168. PubMed ID: 30419471
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
    Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
    Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
    Loffredo L; Perri L; Violi F
    Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
    Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch F; Santamaría A
    J Comp Eff Res; 2019 Feb; 8(3):165-178. PubMed ID: 30654626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
    Norby FL; Alonso A
    J Comp Eff Res; 2017 Sep; 6(6):549-560. PubMed ID: 28737102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
    Petrasko M; Raizada A; Petraskova T
    S D Med; 2016 Aug; 69(8):363-369. PubMed ID: 28806005
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
    Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Simeon L; Wuillemin WA
    Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
    Ašić A; Marjanović D; Mirat J; Primorac D
    Per Med; 2018 May; 15(3):209-221. PubMed ID: 29767545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
    Boehr S; Haen E
    Ther Drug Monit; 2017 Feb; 39(1):66-76. PubMed ID: 27861316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.